Montazerifar Farzaneh, Karajibani Mansour, Lashkaripour Kobra, Yousefi Maryam
Pregnancy Health Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran ; Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran ; Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran.
Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran ; Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran.
Int J High Risk Behav Addict. 2013 Dec;2(3):117-21. doi: 10.5812/ijhrba.14021. Epub 2013 Dec 24.
Adiponectin, an adipocyte-derived protein, modulates a number of metabolic processes. Methadone maintenance treatment (MMT) changes the level of hormones produced by adipose tissue in addicts. However, current data remains contradictory.
The aim of this study was to evaluate the effect of MMT on serum adiponectin levels in drug addicts.
Twenty-five drug abusers with a mean age of 37.4 ± 8.7 years were referred to the Baharan Hospital, Zahedan, and 22 healthy age-matched control subjects with a mean age of 35 ± 9.5 years were enrolled in the study. Addicts were treated with methadone at (40 to 120 mg/d) for six months. Measurement of anthropometric parameters, serum adiponectin, and biochemical parameter levels, were assessed in the addicts, before and after six months of MMT, but only once in the healthy controls.
The mean basal serum adiponectin level was not significantly lower in the drug abuser group compared to the healthy subjects (P > 0.05). After six months of MMT, the mean serum adiponectin level of the drug addicts was not significantly different from their mean baseline level or that of the healthy subjects (P > 0.05). However, the mean baseline serum adiponectin level was significantly lower in overweight/obese addicts when compared to underweight patients and healthy individuals (P < 0.001). After six months of MMT, the mean level of serum adiponectin increased significantly in the underweight subjects compared to the normal weight and overweight/obese subjects (P < 0.0001) and the control group (P < 0.001). Adiponectin concentration was correlated inversely with body mass index and positively correlated with waist circumference and serum high-density lipoprotein levels.
This study showed that MMT did not markedly alter the concentration of serum adiponectin in drug abusers. However, in regard to the variations in the serum lipid profiles and anthropometric parameters, the findings indicated that low concentrations of serum adiponectin might play a role in the pathogenesis of obesity and other metabolic abnormalities. Thus, more long-term studies with larger sample sizes are recommended.
脂联素是一种脂肪细胞衍生蛋白,可调节多种代谢过程。美沙酮维持治疗(MMT)会改变成瘾者体内脂肪组织产生的激素水平。然而,目前的数据仍存在矛盾。
本研究旨在评估MMT对吸毒成瘾者血清脂联素水平的影响。
25名平均年龄为37.4±8.7岁的药物滥用者被转介至扎黑丹的巴哈兰医院,22名年龄匹配的健康对照者(平均年龄为35±9.5岁)被纳入研究。成瘾者接受美沙酮治疗(40至120毫克/天),为期6个月。在MMT治疗6个月前后,对成瘾者进行人体测量参数、血清脂联素和生化参数水平的测量,而健康对照者仅测量一次。
与健康受试者相比,药物滥用者组的平均基础血清脂联素水平无显著降低(P>0.05)。MMT治疗6个月后,吸毒成瘾者的平均血清脂联素水平与其平均基线水平或健康受试者的水平无显著差异(P>0.05)。然而,与体重过轻的患者和健康个体相比,超重/肥胖成瘾者的平均基线血清脂联素水平显著降低(P<0.001)。MMT治疗6个月后,体重过轻的受试者的血清脂联素平均水平与正常体重和超重/肥胖受试者相比显著升高(P<0.0001),与对照组相比也显著升高(P<0.001)。脂联素浓度与体重指数呈负相关,与腰围和血清高密度脂蛋白水平呈正相关。
本研究表明,MMT并未显著改变吸毒成瘾者血清脂联素的浓度。然而,就血脂谱和人体测量参数的变化而言,研究结果表明血清脂联素浓度较低可能在肥胖和其他代谢异常的发病机制中起作用。因此,建议开展更多样本量更大的长期研究。